PROSPECTIVE OBSERVATIONALSTUDY ON SAFETY ANDEFFECTIVENESS OF TRASTUZUMABIN HER- 2 POSITIVE BREAST CANCERPATIENTS

Abstract

Targeting HER-2 receptor cells with the targeted medication trastuzumab, which inhibits the proliferation of cancer cells, is used clinically for HER-2-positive breast cancer patients. Although it is used to treat several other types of cancer, HER-2-positive breast cancer patients benefit more from it. The effectiveness and safety of trastuzumab are the main topics of the study. With few adverse events reported, this therapy is typically well tolerated